Under the agreement, researchers, data scientists and genomics experts from Philips and Sloan Kettering will apply large-scale DNA sequencing and advanced analytics to pancreatic cancer tumors. Using the Philips IntelliSpace Genomics platform, the collaborators will identify single-cell differences between pancreatic cancer tumors.
The project’s goal is to inform personalized cancer treatments based on tumor composition. Philips will share findings from the collaboration through research applications on its platform.
“Collaborating with MSK and its experts will allow us to take a unique approach to diagnosing and treating this devastating disease,” said Henk van Houten, chief technology officer at Philips. “We can gain new insights into the origin, development and optimal treatment of pancreatic cancer, and share these insights broadly with care providers to help improve outcomes for patients.”
More articles on health IT:
mHealth effectively predicts flu outbreaks, study finds
GW researcher awarded $1.2M NIH grant to standardize genomics data
Study: 82% of electronic patient progress notes copied, imported
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
